Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
Título
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
Autor
Kyle Rosenke, Frederick Hansen, Benjamin Schwarz, Friederike Feldmann, Elaine Haddock, Rebecca Rosenke, Kent Barbian, Kimberly Meade-White, Atsushi Okumura, Shanna Leventhal, David W. Hawman, Emily Ricotta, Catharine M. Bosio, Craig Martens, Greg Saturday, Heinz Feldmann, Michael A. Jarvis
Descripción
While vaccines protecting against SARS-CoV-2 infection are approved, currently, there are no drugs suitable for high-risk exposure use against SARS-CoV-2. Here, Rosenke et al. provide evidence that orally delivered MK-4482, a nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model.
Fecha
2021
Identificador
10.1038/s41467-021-22580-8
Fuente
Epidemiology and Health
Editor
Korean Society of Epidemiology
Cobertura
Science
Archivos
Colección
Citación
Kyle Rosenke, Frederick Hansen, Benjamin Schwarz, Friederike Feldmann, Elaine Haddock, Rebecca Rosenke, Kent Barbian, Kimberly Meade-White, Atsushi Okumura, Shanna Leventhal, David W. Hawman, Emily Ricotta, Catharine M. Bosio, Craig Martens, Greg Saturday, Heinz Feldmann, Michael A. Jarvis, “Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model,” SOCICT Open, consulta 17 de abril de 2026, https://socictopen.socict.org/items/show/9044.
Position: 8698 (27 views)